PFA Pension Forsikringsaktieselskab Invests $59.15 Million in Cencora, Inc. $COR

PFA Pension Forsikringsaktieselskab bought a new position in shares of Cencora, Inc. (NYSE:CORFree Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 173,936 shares of the company’s stock, valued at approximately $59,145,000. PFA Pension Forsikringsaktieselskab owned 0.09% of Cencora at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of COR. Marshall Wace LLP grew its position in shares of Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after buying an additional 1,672,762 shares during the period. Mizuho Markets Americas LLC grew its position in shares of Cencora by 116.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after buying an additional 1,511,906 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Cencora by 528.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after purchasing an additional 1,241,186 shares during the period. Viking Global Investors LP grew its position in shares of Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Cencora by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock valued at $7,311,810,000 after purchasing an additional 916,506 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on COR shares. Robert W. Baird set a $415.00 price objective on Cencora in a research report on Tuesday, January 13th. JPMorgan Chase & Co. boosted their price objective on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Bank of America decreased their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research report on Monday, January 5th. Finally, Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $398.17.

View Our Latest Stock Report on Cencora

Cencora Trading Down 1.2%

NYSE COR opened at $304.18 on Friday. The stock has a market capitalization of $59.17 billion, a price-to-earnings ratio of 36.56, a PEG ratio of 1.42 and a beta of 0.65. The stock’s 50 day moving average price is $333.36 and its two-hundred day moving average price is $343.13. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. Cencora, Inc. has a 52 week low of $271.00 and a 52 week high of $377.54.

Cencora (NYSE:CORGet Free Report) last released its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating the consensus estimate of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.73 EPS. As a group, analysts anticipate that Cencora, Inc. will post 17.56 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were paid a $0.60 dividend. The ex-dividend date was Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.8%. Cencora’s payout ratio is presently 28.85%.

About Cencora

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Further Reading

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.